Skip to main content
FDA orphan status granted to NeuroVive's mitochondrial disease drug
4/23/2018

The FDA granted orphan drug status to NeuroVive Pharmaceutical for KL1333, which is being developed as a treatment for patients with inherited mitochondrial respiratory chain diseases.

Full Story: